New drug combo trial aims to outperform standard for Tough-to-Treat breast cancer
Disease control
Recruiting now
This study is testing whether a new oral drug combination (lasofoxifene + abemaciclib) works better than a standard combination (fulvestrant + abemaciclib) for controlling advanced breast cancer that has a specific genetic change (ESR1 mutation) and has worsened after initial hor…
Phase: PHASE3 • Sponsor: Sermonix Pharmaceuticals Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC